Phio Pharmaceuticals Corp. (PHIO)

NASDAQ: PHIO · IEX Real-Time Price · USD
0.768
-0.012 (-1.56%)
At close: May 23, 2024, 4:00 PM
0.774
+0.006 (0.85%)
Pre-market: May 24, 2024, 8:10 AM EDT
-1.56%
Market Cap 3.53M
Revenue (ttm) n/a
Net Income (ttm) -9.38M
Shares Out 4.59M
EPS (ttm) -3.25
PE Ratio n/a
Forward PE 0.31
Dividend n/a
Ex-Dividend Date n/a
Volume 26,997
Open 0.780
Previous Close 0.780
Day's Range 0.740 - 0.780
52-Week Range 0.500 - 4.139
Beta 1.37
Analysts Strong Buy
Price Target 4.00 (+420.97%)
Earnings Date May 9, 2024

About PHIO

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silen... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Robert J. Bitterman
Employees 8
Stock Exchange NASDAQ
Ticker Symbol PHIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for PHIO stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target
$4.0
(420.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Phio to present a clinical study progress update on their lead clinical candidate, PH-762 Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a cli...

15 hours ago - Newsfile Corp

Phio Pharmaceuticals Secures New Investor

MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is des...

6 days ago - GlobeNewsWire

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

- PH-762 is Phio's lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage bio...

8 days ago - GlobeNewsWire

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 – Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio ...

14 days ago - GlobeNewsWire

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

-Phio's lead clinical product candidate, PH-762, is the focus of dermatological poster presentation -Phio's lead clinical product candidate, PH-762, is the focus of dermatological poster presentation

24 days ago - GlobeNewsWire

Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma MA...

4 weeks ago - GlobeNewsWire

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

Phio's lead clinical product candidate, PH-762, is the subject of three new dermatological posters Phio's lead clinical product candidate, PH-762, is the subject of three new dermatological posters

5 weeks ago - GlobeNewsWire

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is d...

6 weeks ago - GlobeNewsWire

National Spotlight Features Phio's Innovative RNAi Technology Platform

—Program will be airing on PBS with Dennis Quaid in April —It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO)...

7 weeks ago - GlobeNewsWire

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

– Four sites across the country participating in clinical trial for lead product candidate PH-762 –  Two patients have already completed treatment – New patent granted for skin related treatments, ext...

7 weeks ago - GlobeNewsWire

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

MARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is d...

2 months ago - GlobeNewsWire

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders

Phio's Compound RXI-185 and RXI-231 designed to treat photo-aging and hyperpigmentation Phio's Compound RXI-185 and RXI-231 designed to treat photo-aging and hyperpigmentation

2 months ago - GlobeNewsWire

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

--New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechn...

4 months ago - GlobeNewsWire

Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds

MARLBOROUGH, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed ...

6 months ago - GlobeNewsWire

Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed ...

7 months ago - GlobeNewsWire

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed ...

7 months ago - GlobeNewsWire

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

Intratumoral injection of INTASYL self-delivering RNAi compound targeting CTLA-4 (27790) in combination with systemic anti-PD-1 antibody therapy offers a novel approach to combination Immune Checkpoin...

7 months ago - GlobeNewsWire

Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed ...

8 months ago - GlobeNewsWire

Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894

--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination

8 months ago - GlobeNewsWire

Phio CEO to Speak at Wainwright Conference in New York in September

He'll address clinical trial progress in Phio's lead product candidate He'll address clinical trial progress in Phio's lead product candidate

9 months ago - GlobeNewsWire

Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute

Trial targeting treatment of metastatic melanoma and other solid tumors Trial targeting treatment of metastatic melanoma and other solid tumors

9 months ago - GlobeNewsWire

Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

MARLBOROUGH, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed ...

10 months ago - GlobeNewsWire

Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

MARLBOROUGH, Mass. , June 2, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to m...

1 year ago - PRNewsWire

Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

MARLBOROUGH, Mass. , May 31, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to m...

1 year ago - PRNewsWire

Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute

One of two newly announced clinical trials for its lead product candidate, PH-762 MARLBOROUGH, Mass. , May 24, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechn...

1 year ago - PRNewsWire